Breaking News
Black Diamond Therapeutics (BDTX) Q4 Loss Narrows to $0.27/Share vs $0.17 Estimate
Black Diamond Therapeutics posted a narrower-than-expected Q4 loss of $0.14/share but missed revenue estimates with zero sales.